TABLE 3.

Results From Multivariate Regression Models of GR Sensitivity Over Time on Fatigue at 1 Month After IMRT

	N	Change in Fatigue	95% CI	p
Delta GR AUC estimate	74	4.07	(0.60 to 7.53)	.022
Baseline fatigue		0.55	(0.35 to 0.76)	<.001
Age		−0.26	(−0.57 to 0.04)	.092
Sex		5.94	(−1.19 to 13.07)	.10
HPV status		3.50	(−3.09 to 10.08)	.30
Marital status		3.53	(−3.00 to 10.06)	.29
Smoking history		−4.53	(−11.30 to 2.23)	.19
Alcohol history		−2.45	(−7.87 to 2.97)	.38
Race		−10.23	(−18.43 to −2.03)	.014
Treatment
Radiation or + surgerya		3.89	(−5.13 to 12.93)	.40
Radiation + carboplatin/paclitaxela		12.40	(3.09 to 21.73)	.009
BMI		−0.10	(−0.72 to 0.53)	.76
Stratified by HPV status adjusted
Delta GR AUC among HPV positive	39	−0.56	(−5.00 to 3.89)	.81
Delta GR AUC among HPV negative	35	8.22	(2.916 to 13.53)	.002

GR = glucocorticoid receptor; IMRT = intensive modulated radiation therapy; CI = confidence interval; AUC = area under the curve; HPV = human papillomavirus; BMI = body mass index.

Adjusted models controlled covariates of baseline fatigue, age, sex, marital status, smoking status, alcohol status, race, treatment, body mass index, and/or human papillomavirus status.

^aCompared with radiation + cisplatin.